USPTO serial 99431659
PROTEIMER
Reviewed by CopyMark Law Group
Status 688Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- ZAVALA DIEK, JOSEPH MARCO
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Deadline: January 7th, 2027
Need help with PROTEIMER?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $648*
Plus Government fees of $300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Carlsbad, CA, US
Carlsbad, CA, US
Carlsbad, CA, US
Carlsbad, CA, US
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Biopharmaceutical preparations for the treatment of cancer and neurological and neurodegenerative diseases; therapeutic proteins, namely, targeted binding proteins engineered for high-affinity and specificity to disease-associated targets, for use in modulating cellular signaling pathways and disease progression; biologic preparations for the treatment of oncological, neurological, metabolic, and immunological disorders; aptamer-based therapeutic agents for targeted treatment of cancer, including immune cell engagers that recruit and activate immune effector cells, including T cells and natural killer (NK) cells, against tumor cells, and for targeted delivery of therapeutic payloads, including cytotoxic agents, nucleic acids, and protein therapeutics, to specific human tissues; protein-based drug candidates, namely, multi-specific and modular biopharmaceutical preparations for the treatment of cancer and neurological and neurodegenerative diseases; antibody mimetics being engineered proteins for targeted modulation of disease pathways, selective receptor agonism or antagonism, blood-brain barrier penetration, and delivery of therapeutic agents to human tissue | ACTIVE | — |
| 042 | Scientific and technological research and design in the fields of biotechnology, pharmaceutical development, research and development of protein-based therapeutics, aptamer-based drug discovery platforms, biologic drug delivery systems, and biologically active molecules for therapeutic use; providing information in the field of scientific research and design in biotechnology | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by HyunDae Cho
- Other trademarks owned by HyunDae Cho
- Other trademarks owned by CrossLife Technologies Inc.
- Other trademarks owned by CrossLife Technologies Inc.
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named PROTEIMER
- Prosecution event NOAM explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 7, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| May 12, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 12, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 6, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 17, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 13, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 13, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Apr 13, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Apr 13, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 9, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 9, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 9, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 26, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 26, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 26, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 25, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 11, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 7, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 7, 2025 | NWAP | NEW APPLICATION ENTERED | — |